Chances are you know someone who has a family member suffering from Alzheimer's disease. Maybe that someone is your own family member. There are roughly 6.2 million people in the United States suffering from Alzheimer's disease. Symptoms can range from emotional distress, including shouting or becoming physically violent. A full 40% of people with Alzheimer's need medical treatment. However, despite the fact that so many people suffer from this disease, there isn't even one drug approved by the FDA designed to treat the agitation that is common in people with Alzheimer's. Many people suffering from this disease are put into long-term care once the agitation becomes too much for their family members to handle. Dr. Herriot Tabuteau is here to change all of that.
Dr. Tabuteau is the CEO of Axsome Therapeutics, a New York-based biopharmaceutical firm that developed a drug called AXS-05. AXS-05 has been called a breakthrough medication for the agitation associated with Alzheimer's disease. The Food and Drug Administration agrees. In December, Axsome started the final phase of the trials needed to apply for full FDA approval. Axsome estimates that the medication will hit the market in 2023. AXS-05 is also thought to be a good option for major depressive disorder as well.
Dr. Herriot Tabuteau immigrated to the U.S. from Haiti when he was nine years old. He attended New York City's Xavier High School where he excelled academically. When he was a junior in high school, he wrote a book called "How to Get A's in School," which was published by New York's LBT Publishing. In 1989, he graduated from Wesleyan University with a bachelor's degree in molecular biology and biochemistry. He went on to attend the Yale School of Medicine graduating with his M.D. in 1994. For his honor thesis, he focused on studying the brain tissue of people who have epilepsy who were resistant to anti-seizure medication. His aim was to study GABA activity, which is the neurotransmitter believed to be able to inhibit seizures. His mentors thought Tabuteau would become a neurosurgeon, but he went into investment banking instead. Armed with his brand new M.D., Tabuteau worked as an analyst for Goldman Sachs where he specialized in healthcare analysis. He went on to work at HealthCor, a fund focused on healthcare and life sciences.
Table of Contents
Biography of Dr. Herriot Tabuteau
Dr. Herriot Tabuteau is a remarkable figure in the field of biopharmaceuticals. His journey began in Haiti, where he faced numerous challenges before moving to the United States. Tabuteau's academic excellence led him to prestigious institutions, culminating in a medical degree from Yale School of Medicine. His diverse career path includes roles in investment banking and healthcare analysis, ultimately leading him to found Axsome Therapeutics.
| Detail | Information |
|---|---|
| Name | Dr. Herriot Tabuteau |
| Birthplace | Haiti |
| Education | Wesleyan University, Yale School of Medicine |
| Profession | CEO of Axsome Therapeutics |
Axsome Therapeutics and AXS-05
Founded in 2012, Axsome Therapeutics focuses on developing innovative treatments for central nervous system disorders. One of their notable products, AXS-05, is designed to alleviate agitation in Alzheimer's patients. The FDA has recognized AXS-05 as a breakthrough therapy, and its expected market release in 2023 could significantly change how agitation is managed in Alzheimer's care.
The success of Axsome Therapeutics reflects Dr. Tabuteau's dedication to improving the lives of those affected by serious health conditions. His vision of creating effective treatments aligns with the urgent need for solutions in the Alzheimer's community.
Impact on Alzheimer's Care
Dr. Tabuteau's work with Axsome Therapeutics is transforming Alzheimer's care by providing hope for better management of its symptoms. His commitment to developing AXS-05 is a significant step toward addressing the agitation that many patients experience, which can often lead to undesirable outcomes, including placement in long-term care facilities.
As AXS-05 approaches the market, it represents not just a new treatment option but also a message of hope for families dealing with the impact of Alzheimer's disease. Dr. Tabuteau's journey illustrates how dedication, innovation, and a focus on patient care can lead to meaningful changes in the healthcare landscape.
